Epistra and Myoridge Successfully Develop AI-Powered Culture Medium for MSCs

Epistra Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yosuke Ozawa) and Myoridge are pleased to announce the successful development of culture media for mesenchymal stem cells (MSCs) through their AI-powered medium development service.

In recent years, regenerative medicine and stem cell therapy have advanced significantly in the medical field, opening new possibilities for patient treatment. MSCs in particular are expected to have therapeutic effects for a wide range of diseases, and their promising areas of application continue to expand.

By combining Epistra’s condition optimization AI algorithm (Epistra Accelerate) with Myoridge’s medium composition database and high-throughput candidate medium production technology, 75 medium compositions with superior proliferative properties compared to the client’s existing media were discovered within approximately 4 months. All developed media are animal-origin-free (AOF), containing no animal or human-derived factors. Long-term culture testing is planned for the next phase.

This success demonstrates the strength of both companies’ technologies and collaborative framework, and we will continue to pursue the application of cutting-edge technologies.